Search Results 721-730 of 8000 for driving with dementia
There is evidence that neurodegenerative changes precede clinical symptoms in Alzheimer's disease by two decades (Villemagne et al, 2013).
A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease · Overview · Participation eligibility.
Alzheimer's disease, which is a progressive brain disorder that is the most common cause of dementia. Aducanumab targets amyloid plaques in the brain that are ...
A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies.
Cerebrospinal Fluid (CSF) Biomarkers for Prediction of Dementia. Rochester, Minn., Jacksonville, Fla. To further investigate biomarkers in CSF as possible ...
The lab has recently shown that obesity leads to an increased accumulation of senescent cells in the liver, driving fatty liver disease, and causes anxiety ...
The purpose of this study is to learn more about amyloid and tau burden in the brain of patients with Atypical Alzheimer's Disease and how that burden may ...
Alzheimer's and dementia: When to stop driving. Related Articles. Mayo Clinic Minute. Mayo Clinic Minute: Battling barriers to transplant surgery. Neurosciences.
A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease ... Alzheimer's disease (AD) ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Make your tax-deductible gift and be a part of the cutting-edge research and care that's changing medicine.